| INTRODUCTION
The onset of direct-acting antiviral agents (DAAs) has led to major advances in hepatitis C virus (HCV) therapy. 1 In clinical trials and in real-life settings, the combination of sofosbuvir (SOF; Gilead, Foster City, USA) and an NS5A inhibitor (daclatasvir [DCV; Bristol-Myers Squibb, NYC, USA] as a standalone drug, or ledipasvir [LDV; Gilead, Foster City, USA] as part as a one-pill fixed-dose combination with SOF [SOF/LDV]) for 12 weeks was shown to be highly efficacious in HCV-infected patients, with an optimal safety profile. However, lower efficacy was reported in treatment-experienced patients with compensated cirrhosis. [2] [3] [4] [5] [6] Therefore, the EASL and AASLD/IDSA guidelines now recommend that the SOF+DCV or SOF/LDV be given with ribavirin (RBV) and/or that treatment duration be extended to 24 weeks without RBV in pegylated interferon (IFN) and RBV-experienced patients with compensated cirrhosis. 7 These recommendations may, however, lead to over-treating a substantial proportion of cirrhotic patients, likely to cure infection after only 12 weeks of therapy without RBV. 3, 8 Thus, it is important to identify which subgroup of these cirrhotic patients does not need to receive reinforced therapy in the real-world setting.
An important parameter is the presence, at treatment baseline, of resistance-associated substitutions (RASs), ie, substitutions that confer resistance to the NS5A inhibitor, which, together with host and disease-related factors, favor treatment failure. Pooled data analysis from Phase 2 and 3 study results with SOF+DCV or SOF/LDV indeed suggest that the presence of NS5A RASs at baseline (as assessed by population sequencing or by deep sequencing with a cutoff of 15%) affects the chance for a sustained virological response (SVR) to these combinations, particularly in cirrhotic and in pegylated IFN and RBV-experienced patients. [9] [10] [11] However, the use of different methodologies in the different cohorts and clinical trials, the nature of the analysed RASs and the fact that most data were generated with HCV genotype 1 make it difficult to measure the actual impact of baseline NS5A RASs on treatment outcomes.
As the costs of generic production of sofosbuvir and NS5A inhibitor are rapidly decreasing, the combination of these DAAs will be the standard treatment in most low-to middle-income countries in the future. Thus, it is important to identify key predictors of response and parameters that can be used to tailor treatment decisions. The goal of the present real-world study, that included a large number of patients treated with SOF plus an NS5A inhibitor, was to characterize the virological response to therapy (including on-treatment viral kinetics and SVR) and to assess the effect of NS5A RASs on these responses.
| PATIENTS AND METHODS

| Patients
The study included 216 nonselected HCV-infected patients, consecutively treated between January 2014 and September 2015 in the Department of Hepatology of the Henri Mondor University Hospital.
The patients' characteristics are presented in 
As no HCV RNA level was measured during the first week of treatment, the clearance of free virus could not be estimated and therefore was fixed at 22 day À1 , as recently described, 12 while p and b were fixed to 10 day À1 and 10 À7 mL.RNA À1 .day À1 , respectively, without loss of generality. 13 Three parameters were esti- Only covariate effects that appeared significant in univariate analysis were tested in the multivariate analysis on all viral kinetic parameters.
Population parameters of the final viral kinetic model were used to simulate a population of 1000 infected patients. The treatment duration needed to cure each simulated patient was predicted using a "cure boundary", defined as having less than 1 virus in the whole body fluid (corresponding to an HCV RNA level lower than 10 À4 viral copies/mL). 14 
| Assessment of HCV resistance to DAAs
The presence of RASs in the NS5A and NS5B regions was assessed at baseline in all patients and at treatment failure in patients who did not achieve SVR by means of population sequencing (sensitivity: approximately 20%), as previously described. 15 The presence at baseline or selection at failure of RASs that confer a more than twofold decrease in drug susceptibility compared to wild-type in vitro and/or of RASs previously reported to be selected in patients with treatment failure 10 was described.
| Statistical analyses
Results are presented as number (percentage) for categorical data, and mean AE standard deviation or median (interquartile range) for continuous data, depending on their distribution.
Predictors 3 | RESULTS
| Baseline characteristics
A cohort of 216 patients consecutively treated in our institution was enrolled ( Figure 1 The results are shown in Table 2 . The SVR12 rates did not differ according to the type of on-treatment response (92.6%, 97.8% and 95.2% in patients with a rapid, early or late response respectively).
Low-level viraemia was detected at EOT in 24.8% of patients, among which 94.2% achieved SVR12, a similar rate to that in patients with undetectable HCV RNA at EOT (94.5%) ( Table 2) .
On-treatment viral kinetic modeling was assessed in patients infected with genotypes 1 and 4, as described in the Methods section. Parameter estimates of the viral kinetic model are shown in Figure S1 ). This prediction contrasted with the fact that the vast majority of patients cleared HCV infection after only 12 weeks of treatment. In addition, there was no significant difference in the model-based predicted HCV RNA levels at the end of treatment between patients who did or did not achieve SVR12. Altogether, our findings suggest that ontreatment viral kinetics (at least during the early interval during which they are measurable) are not predictive of the virological outcome of treatment with a combination of sofosbuvir and an NS5A
inhibitor. Figure 1 
| Virological failures
No virological breakthrough occurred during the treatment period.
Twelve patients experienced post-treatment relapse, including 10 at week 4, 1 between weeks 4 and 12, and 1 between weeks 12 and 24 post treatment (Table 3) . Among the 12 relapses, 11 had received SOF+DCV and one had received SOF/LDV. Three patients were infected with genotype 1 (1 with subtype 1a and 2 with subtype 1b), one with genotype 2, 5 with genotype 3, and 3 with genotype 4. All had compensated cirrhosis, and 10 were treatment-experienced (Table 3) . and 66.6%, respectively; P = .001). In genotype three-infected cirrhotic patients, virological relapse was frequent (15%, n = 5/33), independent of the presence of NS5A RASs at baseline.
| HCV resistance analyses
Of the 12 patients who relapsed post-treatment, eight were found to harbor NS5A RASs at baseline ( Table 3) . The remaining four patients who relapsed were all infected with GT-3, and selected the NS5A Y93H RAS at treatment failure. All patients who relapsed harbored NS5A RASs at treatment failure, whereas none harbored NS5B RASs at either baseline or treatment failure.
| Factors associated with virological failure
The patients' baseline characteristics were included in a multivariable logistic regression analysis of factors independently associated with SVR12 (Table 4 | 669 of failure. Subgroups defined according to gender, age, previous treatment history, pre-treatment HCV RNA levels, and current treatment regimen did not show any impact on the rates of SVR12.
| Safety and tolerability
The combination of SOF plus DCV or LDV was well tolerated. There were no AEs leading to treatment discontinuation. HCC occurred in two cirrhotic patients during the follow-up period of the study (both at follow-up week 12). Three additional SAEs were reported during treatment or within 12 weeks after EOT, including one case of spamous cell carcinoma, one case of colon adenocarcinoma, and pneumonia in one patient, none of which was considered related to study treatment by the investigators.
| DISCUSSION
This real-world cohort provided us with a unique opportunity to investigate the factors associated with the virological response of HCV-infected patients to 12 weeks of therapy with an NS5A inhibitor (either DCV or LDV) combined with SOF without RBV. Indeed, the study was initiated in January 2014, ie, before the establishment of current guidelines recommending the addition of ribavirin and/or prolonged treatment duration according to treatment history and the presence of cirrhosis. 7 The present series included patients infected with various genotypes, and both cirrhotic and noncirrhotic patients.
In noncirrhotic patients, our results were in keeping with current guidelines, showing a 100% SVR12 rate with SOF plus an NS5A inhibitor for 12 weeks without ribavirin, regardless of the HCV genotype and presence of baseline NS5A RASs. In treatment-na€ ıve patients without cirrhosis, the EASL recommendations for treatment of hepatitis C 2016 7 suggest that treatment with SOF/LDV can be shortened to 8 weeks if the baseline HCV RNA level is below 6 million (6.8 Log) IU/mL. This strategy has not been evaluated in our study, but it has been validated by several recent real-world studies 16 confirming that treatment-na€ ıve noncirrhotic patients are easy to cure, regardless of their HCV genotype. receiving SOF+DCV. In this study, SVR12 rates were not impacted by time to first undetectable HCV RNA. 19 In contrast, a recent Spanish multicohort study 20 suggested that the response at treatment week 4 is predictive of SVR in HCV genotype 3-infected patients. The population of this study was however different from that in our study, as patients were receiving different DAA combinations with ribavirin (SOF+DCV+RBV; SOF/LDV+RBV or SOF+RBV).
Further studies are needed to clarify the impact of early monitoring as a predictive marker of SVR, particularly when using first-wave DAAs combinations.
In this study, we also showed for the first time that baseline RASs had no effect on any viral kinetics parameter, suggesting that NS5A RASs do not impact the speed of decline of replicating viruses.
Our results are in keeping with the recent hypothesis that the lack of predictive power of on-treatment viral kinetics on the SVR is due to different factors, in particular the fact that treatment could increase the proportion of non-infectious viruses which would constitute most of the measured viral load. | 671 in a real-world cohort of patients. It suggests that a personalized approach including baseline NS5A inhibitor resistance testing may be informative for treatment decisions in cirrhotic patients. However, this test is unlikely to be widely affordable and reimbursed, particularly in low-to middle-income countries where the combination of generic SOF plus an NS5A inhibitor will become the standard treatment. Therefore, baseline resistance testing could be used to decide about ribavirin add-on or increased treatment duration when it is available and affordable, particularly in difficult to treat-population, such as genotype 3 cirrhotic patients.
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